Setting the Record Straight
By Daniel Cossins,
The Scientist
| 10. 01. 2014
Sometimes even the best-known stories have hidden subplots. This January, Nature published two papers describing an astonishing new way to make stem cells: simply grow blood cells from adult mice in acidic media.1,2 The researchers behind the work—a team from the RIKEN Center for Developmental Biology in Japan and Harvard Medical School—called it stimulus-triggered acquisition of pluripotency, or STAP. These stress-induced stem cells were even more malleable than induced pluripotent stem cells (iPSCs), and, even better, they could be produced without the addition of transcription factors. Naturally, the press was abuzz with the promise of STAP to accelerate stem cell research. But in the less well-lit corners of the Web, some were already raising doubts.
Leading the way was Paul Knoepfler, a stem cell researcher at the University of California, Davis. “I quickly had the feeling this might be entirely wrong,” he says, “and that’s pretty unsettling when it’s in Nature.” On January 29, the day both papers went up online, Knoepfler posted a review of the research on his blog. “It just seems too good...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...